{"id":"cpg-odn","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CpG-ODN works by mimicking the effects of bacterial DNA, which triggers an immune response. This leads to the activation of various immune cells, including dendritic cells and T cells, which play a crucial role in fighting infections and diseases.","oneSentence":"CpG-ODN is a synthetic DNA molecule that acts as an immunostimulant by activating the immune system through Toll-like receptor 9 (TLR9).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:09:14.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers, including melanoma and non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06622434","phase":"PHASE1, PHASE2","title":"New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-08","conditions":"Newly Diagnosed Glioblastoma","enrollment":35},{"nctId":"NCT07025564","phase":"PHASE1","title":"MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-02-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05279456","phase":"PHASE3","title":"A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2022-08-15","conditions":"COVID-19","enrollment":39},{"nctId":"NCT05542862","phase":"PHASE3","title":"Booster Study of SpikoGen COVID-19 Vaccine","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2022-09-07","conditions":"COVID-19","enrollment":81},{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT03410901","phase":"PHASE1","title":"TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Ronald Levy","startDate":"2018-04-09","conditions":"B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma","enrollment":14},{"nctId":"NCT02927964","phase":"PHASE1, PHASE2","title":"TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma","status":"COMPLETED","sponsor":"Robert Lowsky","startDate":"2016-11-07","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":21},{"nctId":"NCT06047015","phase":"PHASE1, PHASE2","title":"Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-07","conditions":"Liver Metastasis Colon Cancer","enrollment":12},{"nctId":"NCT05148871","phase":"PHASE2, PHASE3","title":"Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2022-03-01","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04952272","phase":"PHASE1","title":"Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-03-01","conditions":"Lung Cancer, Hepatocellular Carcinoma, Solid Tumor","enrollment":50},{"nctId":"NCT04995536","phase":"PHASE1","title":"CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2021-07-27","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":""},{"nctId":"NCT03831295","phase":"PHASE1","title":"SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies","status":"COMPLETED","sponsor":"Ronald Levy","startDate":"2019-03-13","conditions":"Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":12},{"nctId":"NCT05285384","phase":"NA","title":"Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2022-02-04","conditions":"COVID-19","enrollment":43},{"nctId":"NCT05231590","phase":"PHASE3","title":"Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2022-02-23","conditions":"COVID-19","enrollment":581},{"nctId":"NCT05175625","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2021-12-15","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05005559","phase":"PHASE3","title":"Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2021-08-07","conditions":"Covid19","enrollment":16876},{"nctId":"NCT04944368","phase":"PHASE2","title":"Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2021-05-30","conditions":"Covid19","enrollment":400},{"nctId":"NCT04962893","phase":"PHASE2","title":"Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine","status":"COMPLETED","sponsor":"Ihsan GURSEL, PhD, Prof.","startDate":"2021-06-26","conditions":"Covid19","enrollment":349},{"nctId":"NCT04818281","phase":"PHASE1","title":"Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Ihsan GURSEL, PhD, Prof.","startDate":"2021-03-27","conditions":"Covid19","enrollment":38},{"nctId":"NCT04453852","phase":"PHASE1","title":"Monovalent Recombinant COVID19 Vaccine","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2020-06-30","conditions":"Coronavirus Infection, COVID","enrollment":40},{"nctId":"NCT03373214","phase":"PHASE1","title":"Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2018-02-01","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT04428073","phase":"PHASE1","title":"Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","status":"UNKNOWN","sponsor":"GeneCure Biotechnologies","startDate":"2020-07","conditions":"COVID","enrollment":32},{"nctId":"NCT02254772","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Intratumoral Injection of SD-101","status":"COMPLETED","sponsor":"Robert Lowsky","startDate":"2014-09","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":9},{"nctId":"NCT00640861","phase":"EARLY_PHASE1","title":"Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08-28","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT00824733","phase":"PHASE2","title":"Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Bhuvaneswari Ramaswamy","startDate":"2009-02","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT01035216","phase":"PHASE1","title":"A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)","status":"TERMINATED","sponsor":"SBI Biotech Co., Ltd.","startDate":"2009-09","conditions":"Leukemia","enrollment":18},{"nctId":"NCT01164514","phase":"PHASE1","title":"Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-11","conditions":"Bacterial Sepsis","enrollment":20},{"nctId":"NCT00190424","phase":"PHASE2","title":"Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-09","conditions":"Glioblastoma","enrollment":80},{"nctId":"NCT00100633","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-12","conditions":"HIV Infections, Hepatitis B","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2272,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CpG-ODN","genericName":"CpG-ODN","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CpG-ODN is a synthetic DNA molecule that acts as an immunostimulant by activating the immune system through Toll-like receptor 9 (TLR9). Used for Treatment of various cancers, including melanoma and non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}